Canaccord Genuity analyst John Newman reiterated a Buy rating on Agios Pharma (AGIO) on February 15 and set a price target of $75. The company’s shares closed yesterday at $57.71.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 12.9% and a 43.2% success rate. Newman covers the Healthcare sector, focusing on stocks such as Selecta Biosciences, Bluebird Bio, and Celgene.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agios Pharma with a $85 average price target, a 47.3% upside from current levels. In a report issued on February 14, Piper Jaffray also maintained a Buy rating on the stock with a $100 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $99.82 and a one-year low of $41.63. Currently, Agios Pharma has an average volume of 562.8K.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGIO in relation to earlier this year. Most recently, in December 2018, Scott Biller, the CSO of AGIO bought 20,500 shares for a total of $47,765.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
